![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Graceway Pharmaceuticals, LLC |
---|---|
Information provided by: | Graceway Pharmaceuticals, LLC |
ClinicalTrials.gov Identifier: | NCT00117871 |
The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks.
A second purpose is to evaluate the safety of the drug.
Condition | Intervention | Phase |
---|---|---|
Warts |
Drug: Resiquimod |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Single Blind, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 1515-RESI |
Study First Received: | June 30, 2005 |
Last Updated: | February 16, 2007 |
ClinicalTrials.gov Identifier: | NCT00117871 |
Health Authority: | United States: Food and Drug Administration |
Warts Adults Common Warts Resiquimod |
Virus Diseases Skin Diseases, Infectious Warts |
Skin Diseases DNA Virus Infections Papillomavirus Infections |
Skin Diseases, Viral Neoplasms Tumor Virus Infections |